10.17MMarket Cap-26P/E (TTM)
8.050High7.910Low9.48KVolume8.030Open8.012Pre Close76.00KTurnover0.79%Turnover Ratio0.08P/E (Static)1.27MShares82.00052wk High4.92P/B9.59MFloat Cap6.80052wk Low--Dividend TTM1.20MShs Float22220.000Historical High--Div YieldTTM1.75%Amplitude6.425Historical Low8.019Avg Price1Lot Size
Redhill Biopharma Stock Forum
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204
Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) comp...
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
Benzinga· 2 mins ago
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
RedHill Biopharma (Nasdaq: RDHL) has announced that the FDA has granted orphan-drug designation to opaganib for the treatment of neuroblastoma, a rare childhood cancer.
This designation provides seven years of marketing exclusivity if approved and may offer additional benefits such as accelerated development and review times, potential grant funding, and tax credits...
Benzinga· 1 min ago
The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-cont...
No comment yet